Common use of Population Estimates Clause in Contracts

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates. These population estimates of Illinois for all races, whites, blacks, and Asian/other races from 1986 through 2019, and for Hispanics, non-Hispanics, non-Hispanic white, and non-Hispanic black for 1990 through 2019 were obtained from both the intercensal and Vintage 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race, and Hispanic origin were produced by the United States Bureau of Census Population Estimates Program in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2020 (for 2010‐2019) bridged single‐race estimates are derived from the original multiple race categories in the 2000 and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Because of the way cancers are grouped in this report, these changes would have slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1995-1999, 2000-2004, 2005-2009 (this and prior groups not available for the Cook County file), 2010-2014, and 2015-2019).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates. These population estimates of Illinois for all races, whites, blacks, and Asian/other races from 1986 through 20192020, and for Hispanics, non-Hispanics, non-Hispanic white, and non-Hispanic black for 1990 through 2019 2020 were obtained from both the intercensal and Vintage 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race, and Hispanic origin were produced by the United States Bureau of Census Population Estimates Program in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2020 (for 2010‐20192010‐2020) bridged single‐race estimates are derived from the original multiple race categories in the 2000 and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Because of the way cancers are grouped in this report, these changes would have slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (19951996-19992000, 20002001-20042005, 20052006-2009 2010 (this and prior groups not available for the Cook County file), 20102011-20142015, and 20152016-20192020).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates. These population estimates of Illinois for all races, whites, blacks, and Asian/other races from 1986 through 20192017, and for Hispanics, non-Hispanics, non-Hispanic white, and non-Hispanic black for 1990 through 2019 2017 were obtained from both the intercensal and Vintage 2020 2018 bridged-race post censal population estimates files. Population estimates by age, sex, race, and Hispanic origin were produced by the United States Bureau of Census Population Estimates Program in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐20092000-2009) and Vintage 2020 2018 (for 2010‐20192010-2017) bridged single‐race single-race estimates are derived from the original multiple race categories in the 2000 and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). The bridged single‐race single-race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myelodysplastic Myolodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Because of the way cancers are grouped in this report, these changes would have slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (19951993-19991997, 20001998-20042002, 20052003-2009 2007 (this and prior groups not available for the Cook County file), 20102008-20142012, and 20152013-20192017).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-race- specific groups in five-year age categories, were used as denominators in the formulation of rates. These population estimates of Illinois for all races, whites, blacks, and Asian/other races from 1986 through 20192017, and for Hispanics, non-Hispanics, non-Hispanic white, and non-Hispanic black for 1990 through 2019 2017 were obtained from both the intercensal and Vintage 2020 2018 bridged-race post censal population estimates files. Population estimates by age, sex, race, and Hispanic origin were produced by the United States Bureau of Census Population Estimates Program in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐20092000-2009) and Vintage 2020 2018 (for 2010‐20192010-2017) bridged single‐race single-race estimates are derived from the original multiple race categories in the 2000 and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). The bridged single‐race single-race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Because of the way cancers are grouped in this report, these changes would have slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1995-1999, 2000-2004, 2005-2009 (this and prior groups not available for the Cook County file), 2010-2014, and 2015-2019).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates. These population estimates of Illinois for all races, whitesWhites, blacksBlacks, and Asian/other races from 1986 through 2019, and for Hispanics, non-Hispanics, non-Hispanic whiteWhite, and non-Hispanic black Black for 1990 through 2019 were obtained from both the intercensal and Vintage 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race, and Hispanic origin were produced by the United States Bureau of Census Population Estimates Program in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2020 (for 2010‐2019) bridged single‐race estimates are derived from the original multiple race categories in the 2000 and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence mortality rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Because of the way cancers are grouped in this report, these changes would have slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1995-1999, 2000-2004, 2005-2009 (this and prior groups not available for the Cook County file), 2010-2014, and 2015-2019).

Population Estimates. The population estimates of the sex- and race-specific, as well as sex- and ethnicity/race-specific groups in five-year age categories, were used as denominators in the formulation of rates. These population estimates of Illinois for all races, whitesWhites, blacksBlacks, and Asian/other races from 1986 through 20192020, and for Hispanics, non-Hispanics, non-Hispanic whiteWhite, and non-Hispanic black Black for 1990 through 2019 2020 were obtained from both the intercensal and Vintage 2020 bridged-race post censal population estimates files. Population estimates by age, sex, race, and Hispanic origin were produced by the United States Bureau of Census Population Estimates Program in collaboration with the National Center for Health Statistics, and with support from the National Cancer Institute (NCI) through an interagency agreement. The population estimates incorporate intercensal (for 2000‐2009) and Vintage 2020 (for 2010‐20192010‐2020) bridged single‐race estimates are derived from the original multiple race categories in the 2000 and 2010 Censuses (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). The bridged single‐race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics website. The intercensal estimates provide an adjustment of previous population estimates based on the actual 2010 census results.7,8 Previous estimates utilized prior to the availability of the 2010 census data were prone to increased error as the time from the actual 2000 census increased. At the national level, estimates using both the 2000 census and the 2010 census are not very different from the previous estimates. However, there are more significant differences at the state and county levels that may result in changes to cancer incidence mortality rates when one compares this report to earlier versions. Changes in rates also could be attributable to the addition of cases reported late. Cancer Site Coding for Incidence Data: Although the anatomic site and morphology for cancer cases diagnosed prior to 2001 were coded using the International Classification of Diseases for Oncology version 2 (ICD-O-2)5 and for cancer cases diagnosed in 2001 through 2009, the version 3 (ICD-O-3),6 all ICD-O-2 coded cases were converted to version 3 codes. The ISCR Web-based query data utilizes the ICD-O-3 recode with adjustment for WHO 2008 hematopoietic. SEER-NCI recommends this site recode scheme (Site Recode ICD-O-3/WHO 2008) be used for any data containing cases diagnosed in 2010 or later years. In the interests of comparability to other national, state and registry specific data, subsequent versions of the Web-based query data containing cases diagnosed in 2010 or later will indeed use the SEER Site Recode ICD-O-3/WHO 2008. For a complete listing, see Appendix B of the annual state report (see Illinois State Cancer Incidence Review and Update). Data at the county level in this application are aggregated into 24 major site groups and at the ZIP codes level into 11 site groups. These standardized classification schemes allow direct comparisons of Illinois data with international, national, and state publications. Several definitional changes occurred in some histologies and behaviors in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. These changes may affect the comparability of data between rates prior to 2001 and 2001 or later. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. Several cancers that previously were not coded as malignant in ICD-O-2 are coded as malignant in ICD-O-3. For example, Myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (CMPD) are considered malignant cancer in ICD-O-3, as are papillary ependymomas and papillary meningiomas, which according to ICD-O-3, are included in the “Brain and Nervous System” and “All Cancers Combined” categories. Some endometrial tumors also are classified as malignant in ICD-O-3. Conversely, some low malignant potential tumors of the ovary and pilocytic astrocytomas are no longer coded as malignant in ICD-O-3. Because of the way cancers are grouped in this report, these changes would have slight or little impact on incidence of a specific cancer site; however, it might result in a noticeable increase in cancer incidence rates for “All Cancers Combined.” In addition, both Kaposi sarcoma and mesothelioma are classified as separate site groups within the SEER recode. This change has a slight impact on cancer incidence rates for a few specific cancers, compared to using the previous site grouping method. Counts and rates were calculated for invasive cancers only, with the exception of in situ cancer of the bladder. Although counts and rates for breast cancer in situ are displayed in a separate table, these cases were not included in any counts or rates of all sites combined incidence. Confidentiality of the incidence data is maintained by aggregating data within individual records into categories, the number of which depend on the size of the geographic area. Individual year of diagnosis is available for the Illinois data files, however, for the county, ZIP code, Cook County and stage files, the diagnosis year is a five-year aggregate (1995-1999, 2000-2004, 2005-2009 (this and prior groups not available for the Cook County file), 2010-2014, and 2015-2019).